HLTH Europe 2026 once again brought together the people shaping the future of healthcare. Held in Amsterdam from June 15–18, the event welcomed more than 5,000 attendees, 400+ speakers, 350+ sponsors, and representatives from 65+ countries, making it one of Europe's largest gatherings dedicated to healthcare innovation. Around one in three attendees held C-suite positions, reinforcing HLTH Europe's role as a meeting point for the industry's key decision-makers.
This year also marked our fourth consecutive year attending HLTH Europe. As in previous years, the event offered far more than a glimpse into emerging technologies—it provided a clear picture of where the healthcare industry is heading and which priorities are beginning to define its next stage of transformation.
Across the AI Stage, Global Pharma Summit, Health Transformation Summit, Provider Spotlight, and dozens of expert panels, one message became increasingly clear: healthcare is moving beyond experimentation. The conversation is no longer centered on whether technologies like artificial intelligence, advanced analytics, or digital health platforms have a place in healthcare. Instead, the focus has shifted toward implementing these innovations responsibly, integrating them into existing care models, and demonstrating measurable value for patients, providers, and healthcare organizations alike.
After four days of discussions with healthcare leaders, technology companies, providers, pharmaceutical organizations, investors, and policymakers, several themes consistently emerged. Below are the key takeaways we believe will shape the future of healthcare long after this year's conference.
AI Has Entered Its Implementation Era
Artificial intelligence remained the dominant topic throughout HLTH Europe 2026, but the conversation has noticeably matured. Just a few years ago, most discussions revolved around AI's potential—what it could automate, how quickly it might transform healthcare, or whether organizations were ready to adopt it at all. This year, those questions were largely absent. Instead, the focus shifted toward implementation, governance, and measurable outcomes.
The industry's mindset has evolved from experimentation to execution. Healthcare organizations are no longer asking whether AI belongs in clinical and operational workflows; they're asking how to deploy it responsibly, integrate it into existing systems, and ensure it delivers tangible value. That shift was evident across the AI Stage and echoed throughout discussions in other conference tracks, demonstrating that AI is no longer treated as a standalone innovation topic. Instead, it has become an integral part of broader conversations about care delivery, workforce transformation, and operational efficiency.
One recurring theme was the emergence of AI as a practical assistant rather than a replacement for healthcare professionals. Many discussions centered on reducing administrative burden, streamlining documentation, improving access to information, and helping clinicians spend more time with patients. Ambient clinical documentation, intelligent workflow automation, AI-powered knowledge retrieval, and conversational interfaces all illustrated the same principle: the most successful implementations augment human expertise instead of attempting to replace it.
This reflects an important shift in how healthcare organizations evaluate AI projects. Rather than pursuing automation for its own sake, they increasingly focus on solving well-defined operational challenges. Can AI reduce clinician burnout by eliminating repetitive administrative work? Can it shorten patient waiting times? Can it help healthcare staff access relevant information more quickly? These questions are replacing broader conversations about technological capability.
However, implementation was only one part of the discussion. Equally prominent was the growing recognition that scaling AI requires governance from the very beginning. As healthcare organizations move beyond pilots, they face new responsibilities around transparency, accountability, security, and regulatory compliance. Questions surrounding explainability, human oversight, data privacy, and risk management appeared repeatedly throughout conference discussions, highlighting that successful AI adoption depends as much on organizational readiness as it does on technical sophistication.
This is particularly important in healthcare, where AI systems influence decisions that directly affect patient outcomes. Unlike many other industries, healthcare cannot afford opaque decision-making or uncontrolled automation. Organizations increasingly recognize that AI should support clinical judgment—not replace it—and that clear boundaries must exist regarding when automated systems can act independently and when human intervention remains essential.
Another noticeable shift was the growing interest in agentic AI. Rather than viewing AI as a single chatbot or isolated feature, many organizations are beginning to explore systems capable of orchestrating multiple tasks across complex workflows. From preparing clinicians with relevant patient information before appointments to coordinating administrative processes across departments, AI is gradually evolving into an operational layer that supports the entire healthcare ecosystem. While these capabilities remain in different stages of maturity, the direction is becoming increasingly clear: AI is moving beyond answering questions toward actively assisting with work.
Perhaps the strongest takeaway from HLTH Europe 2026 is that competitive advantage will no longer come from simply adopting AI. The technology itself is becoming widely accessible. What will distinguish healthcare organizations over the coming years is how effectively they integrate AI into existing workflows, govern its use, build trust among clinicians and patients, and continuously improve its performance over time. In other words, success will depend less on having AI and more on implementing it responsibly, strategically, and with a clear understanding of the problems it is meant to solve.
Healthcare Data Is Becoming a Strategic Asset
If AI was the headline topic at HLTH Europe 2026, data was the thread connecting nearly every conversation. Whether discussions focused on clinical decision support, operational efficiency, precision medicine, or pharmaceutical innovation, they all pointed to the same conclusion: meaningful AI is impossible without high-quality, accessible, and interoperable data.
For years, healthcare organizations have accumulated enormous volumes of information, from electronic health records and diagnostic imaging to laboratory results, wearable devices, and patient-generated health data. The challenge has never been collecting data—it has been making it usable. Much of that information still resides in disconnected systems, follows different standards, or remains inaccessible to the teams and technologies that could benefit from it most.
This challenge was reflected across multiple conference tracks, where conversations increasingly shifted away from the quantity of available data and toward its quality, structure, and accessibility. Organizations are beginning to recognize that data should no longer be viewed as a byproduct of healthcare operations. Instead, it has become a strategic asset capable of improving clinical decision-making, enabling more personalized care, supporting medical research, and powering the next generation of AI applications.
Interoperability naturally emerged as one of the central themes. As healthcare ecosystems become increasingly digital, the ability to exchange information seamlessly across hospitals, clinics, laboratories, pharmacies, insurers, and technology platforms is becoming essential rather than optional. Without interoperable systems, even the most advanced AI solutions struggle to provide meaningful value, as they operate on fragmented or incomplete information. Conversely, when data flows securely across organizations, clinicians gain a more comprehensive view of each patient's journey, enabling faster, better-informed decisions.
Within the European context, many discussions also reflected the growing importance of initiatives such as the European Health Data Space (EHDS), which aims to establish a more consistent framework for sharing and using health data across member states. While implementation will take time, the broader direction is clear: healthcare organizations are preparing for a future where secure, standardized, and cross-border data exchange becomes a fundamental part of delivering care and accelerating innovation.
Another recurring topic was the growing role of real-world data and real-world evidence. Clinical trials remain essential for evaluating new therapies, but they represent only part of the picture. Increasingly, healthcare organizations and pharmaceutical companies are looking to understand how treatments perform in routine clinical practice across diverse patient populations. Data collected through everyday care, remote monitoring technologies, connected medical devices, and patient-reported outcomes is becoming an increasingly valuable source of insight for both clinical and commercial decision-making.
However, expanding access to healthcare data also raises important questions around privacy, security, and trust. Patients expect their information to be protected, regulators require strict compliance, and healthcare organizations must balance innovation with responsible data stewardship. These considerations were not presented as barriers to progress but as essential foundations for building sustainable digital health ecosystems. Organizations that invest in strong governance today are likely to be better positioned to scale future AI and analytics initiatives with confidence.
Ultimately, one message became increasingly clear throughout HLTH Europe 2026: data infrastructure is no longer simply an IT concern. It is becoming a core business capability. The organizations that succeed in the coming years will not necessarily be those with access to the largest datasets, but those capable of transforming fragmented information into trusted, connected, and actionable intelligence. As AI continues to mature, data quality, interoperability, and governance will increasingly determine which innovations deliver measurable value and which remain stuck in pilot projects.
Pharma Is Becoming a Technology Industry
The Global Pharma Summit highlighted another significant transformation taking place across the healthcare ecosystem. While pharmaceutical companies have long been associated with scientific research and drug development, they are increasingly evolving into technology-driven organizations that leverage data, AI, and digital platforms across nearly every stage of the product lifecycle.
Artificial intelligence naturally remains one of the key drivers of this transformation, particularly in research and development. AI-powered models are helping researchers identify promising drug candidates, analyze complex biological data, predict molecular behavior, and prioritize compounds for further investigation. These capabilities have the potential to accelerate early-stage discovery while allowing researchers to focus their efforts on the most promising opportunities. However, discussions throughout the conference made it clear that AI's role extends far beyond the laboratory.
Clinical development is also undergoing rapid change. Pharmaceutical companies are increasingly exploring decentralized and hybrid clinical trials that combine traditional research sites with digital tools capable of capturing patient data remotely. Connected medical devices, wearable technologies, mobile applications, and virtual patient interactions are making it possible to collect real-world information more continuously while reducing the burden on trial participants. Beyond improving the patient experience, these approaches have the potential to accelerate recruitment, increase participant diversity, and generate richer datasets that more accurately reflect routine clinical practice.
Another recurring theme was the growing importance of real-world evidence. While randomized clinical trials remain the gold standard for evaluating safety and efficacy, pharmaceutical companies increasingly recognize the value of understanding how therapies perform after they reach the market. Data generated through electronic health records, patient registries, remote monitoring programs, and digital health platforms provides valuable insights into treatment effectiveness, long-term outcomes, adherence, and patient behavior across broader populations. These insights are influencing not only regulatory and clinical decisions but also commercial strategies and market access planning.
Patient engagement has become another strategic priority. Rather than interacting with patients only through healthcare providers, pharmaceutical organizations are investing in digital platforms that support education, treatment adherence, symptom tracking, and ongoing communication throughout the patient journey. This reflects a broader shift toward more patient-centric models of care, where technology helps strengthen relationships beyond the point of prescription and enables more personalized support over time.
Technology is also reshaping commercial operations. AI-driven analytics, predictive modeling, and automation are helping pharmaceutical companies better understand market dynamics, optimize resource allocation, identify emerging opportunities, and personalize engagement with healthcare professionals. At the same time, digital platforms are improving collaboration across research, clinical, regulatory, and commercial teams, allowing organizations to make faster and more informed decisions in an increasingly complex environment.
Despite this rapid technological progress, one message remained consistent throughout the Global Pharma Summit: innovation alone is not enough. Successfully integrating AI and digital technologies requires high-quality data, robust governance, regulatory compliance, and close collaboration across the healthcare ecosystem. Pharmaceutical companies are increasingly recognizing that breakthrough therapies depend not only on scientific excellence, but also on digital capabilities that support faster research, more efficient development, better collaboration with providers, and improved patient outcomes.
Taken together, these discussions point to a broader industry transformation. Pharmaceutical companies are no longer simply developing medicines—they are building digital capabilities that enable them to discover, develop, deliver, and continuously improve therapies throughout their lifecycle. In many ways, technology is becoming just as fundamental to the future of pharma as biology and chemistry themselves.
Wrapping It Up
HLTH Europe has always offered a glimpse into where healthcare is heading, but this year's event suggested something different. Rather than introducing a single breakthrough technology or defining trend, it reflected the growing maturity of the industry's digital transformation.
Artificial intelligence remains at the center of that transformation, but the conversation has clearly evolved. Success is no longer measured by the ability to experiment with new technologies. It is measured by the ability to implement them responsibly, support healthcare professionals, improve patient outcomes, and integrate them into increasingly complex healthcare ecosystems.
Across every conference track—from the AI Stage and Provider Spotlight to the Global Pharma Summit and Health Transformation Summit—the same priorities continued to emerge. Organizations are investing in stronger data foundations, redesigning care delivery, embracing digital capabilities across the pharmaceutical lifecycle, and building partnerships that extend far beyond traditional organizational boundaries.
As we reflect on our fourth consecutive year at HLTH Europe, one conclusion stands out above all others. The future of healthcare will not be shaped by artificial intelligence alone, nor by individual organizations pursuing innovation independently. It will be built through collaboration between providers, technology companies, pharmaceutical organizations, policymakers, and countless other stakeholders working toward a common goal: delivering more accessible, efficient, and patient-centered healthcare.
